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The study reported here investigated the immunogenicity and protective potential of a lipid core peptide
(LCP) construct containing a conserved region determinant of M protein, defined as peptide J8. Parenteral
immunization of mice with LCP-J8 led to the induction of high-titer serum immunoglobulin G J8-specific
antibodies when the construct was coadministered with complete Freund’s adjuvant (CFA) or administered
alone. LCP-J8 in CFA had significantly enhanced immunogenicity compared with the monomeric peptide J8
given in CFA. Moreover, LCP-J8/CFA and LCP-J8 antisera opsonized four different group A streptococcal
(GAS) strains, and the antisera did not cross-react with human heart tissue proteins. These data indicate the
potential of an LCP-based M protein conserved region GAS vaccine in the induction of broadly protective
immune responses in the absence of a conventional adjuvant.
The development of a vaccine against group A streptococci
(GAS)—the etiologic agents of rheumatic heart disease—has
focused largely on the bacterial surface M protein (10, 21). The
M protein is a major virulence factor in GAS infection and
consists of a variable amino-terminal region which defines the
GAS serotype (over 100 serotypes are known) and a highly
conserved carboxy-terminal C-repeat region (10). Protective
immunity to GAS infection has been associated with type-
specific opsonic antibodies against M protein (10, 21), al-
though the presence of opsonic antibodies specific to the C-
region has been demonstrated in humans (17) and in mice
immunized with C-region peptides (18) and is also important
in the elicitation of protective immunity to GAS (4). The vari-
ability in M proteins and the potential for the induction of
autoimmunity due to antigenic molecular mimicry between the
GAS M protein and heart antigens (6, 11, 13, 19) represent
significant hurdles in the development of a vaccine covering a
wide range of strains. Multivalent M protein constructs con-
taining epitopes from several type-specific regions of different
M proteins (4, 7, 8) and those based on the conserved C-region
(2–5) have shown promising results in animal trials. However,
the GAS vaccine constructs require for their efficacy the use of
adjuvants that are not suitable for use in humans due to their
toxicity. The development of novel synthetic adjuvants offers
the possibility of vaccine delivery without the need for addi-
tional toxic adjuvants. Lipopeptide compounds utilizing a syn-
thetic analog of the N-terminal moiety of bacterial lipoprotein
from Escherichia coli (Pam3cys [tripalmitoyl-S-glyceryl cys-
teine]) as a lipidic anchor moiety (26) were found to be potent
immunogens with self-adjuvanting properties, eliciting hu-
moral and cellular responses irrespective of the route of ad-
ministration (9, 15, 16, 27). The lipidic polylysine core peptide
(LCP) system (24) has also been described as using a lipidic
anchor moiety in conjunction with the multiple antigenic pep-
tide system (23). Furthermore, lipopeptide compounds are po-
tentially safe options for vaccine delivery in humans (1). The
study reported here investigated the LCP system as a self-
adjuvanting GAS vaccine delivery approach. An LCP construct
(LCP-J8) was synthesized by incorporating multiple copies of a
GAS M protein C-region peptide, referred to as J8, which
contains a conformational B-cell epitope and lacks potentially
deleterious T-cell autoepitopes (14). The J8 peptide (QA
EDKVKQSREAKKQVEKALKQLEDKVQ, consisting of res-
idues 344 to 355 of the GAS M1 protein) is a chimeric peptide
that contains 12 amino acids from the C-region (shown in bold)
and is flanked by GCN4 DNA-binding protein sequences,
which are required to maintain the correct helical folding and
conformational structure of the peptide (20). J8 was synthe-
sized by manual solid-phase peptide synthesis using Boc (tert-
butoxycarbonyl) chemistry (22), and peptide purification was
carried out on a Waters HPLC system (model 600 controller,
490 E UV detector, 60 F pump).
Boc-L-amino acids and MBHA (4-methylbenzhydrylamine)
resin (Novabiochem, Läufelfingen, Switzerland) were used to
synthesize the LCP-J8 construct (Fig. 1). Racemic lipoamino
acids were synthesized with Boc protection according to the
procedures of Gibbons et al. (12). Preactivated Boc-Gly-OH
was coupled to the MBHA resin. The next two cycles were
carried out with Boc-lipoamino acids containing 12 carbon
atoms (C12: HN-CH[(CH2)9CH3]-OH); this was followed se-
quentially by the coupling of Boc-Gly-OH, Boc-C12-OH, and
Boc-Lys(Boc)-OH. After deprotection of the lysine - and
ε-amino groups, a four-branch system was formed by the cou-
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pling of Boc-Lys(Boc)-OH to the free amino groups. After
deprotection, four identical peptide J8 sequences were synthe-
sized directly onto each of the - and ε-amino groups of each
lysine of the branched lysine core, with the appropriate pro-
tecting groups applied on the side chains of the amino acids.
Thus, the lipophilic anchor of the LCP-J8 construct contains
three 2-amino-dodecanoic lipoamino acids attached to the
polylysine core, with glycine spacers employed—one between
the resin and the first lipoamino acid and another between the
second and third lipoamino acids. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis resulted in a band for
LCP-J8 of the expected size. Determination of the mass spec-
trum of LCP-J8 resulted in a calculated molecular weight of
14,158.45.
To assess the immunogenicity of the LCP-J8 construct, im-
munoglobulin G (IgG) antibody responses to the peptide J8
were measured in sera from 4- to 6-week-old female B10.BR
mice (Animal Resource Centre, Perth, Australia) In two sep-
arate experiments, the mice (n  10 per group) were immu-
nized subcutaneously at the tail base with 30 g of LCP-J8
construct, which was either emulsified 1:1 (vol/vol) with com-
plete Freund’s adjuvant (CFA) (Sigma, Castle Hill, Australia)
or given alone in a total volume of 50 l of sterile-filtered
phosphate-buffered saline (PBS) (Fig. 2). Three weeks after
the primary immunization, the mice received at weekly inter-
vals a further four (experiment 1 [exp 1]) or five (experiment 2
[exp 2]) booster injections of doses of 3 g of LCP-J8 construct
in PBS prior to the collection of blood via the tail artery. Mice
in the control group received 30 g of J8 in CFA or 20 g of
pepM1 (the amino-terminal half of the M protein) in CFA,
with booster injections of 3 g each. Antibody titers were
determined by enzyme-linked immunosorbent assay (18) and
defined as the lowest dilutions that gave optical density (OD)
readings at 450 nm more than three standard deviations above
the mean OD of control wells containing normal mouse sera
(obtained from mice immunized with CFA in PBS). In the first
experiment (Fig. 2A), in which mice received a primary immu-
nization and four booster injections each of the same immuno-
gen, J8-specific antibodies were detected in all mice 3 weeks
after the primary immunizations with LCP-J8 in CFA and J8 in
CFA, with final average antibody titers after four booster in-
jections of 1.5  106 and 1.4  105, respectively (exp 1) (Fig.
FIG. 1. Chemical structure of the LCP-J8 construct. Four identical peptide J8 sequences were synthesized directly onto the two amino groups
of each lysine (Lys) of a branched polylysine core. The lipophilic anchor of the LCP-J8 construct contains three 2-amino-dodecanoic lipoamino
acids (shown as branched alkyl side chains) attached to the polylysine core, with one glycine amino acid spacer between the resin and the first
lipoamino acid and a second between the second and third lipoamino acids.
FIG. 2. Serum IgG antibody response in B10.BR mice immunized parenterally with the LCP-J8 construct in the presence and absence of CFA
for exp 1 (A) and exp 2 (B). Antibody titers to the J8 peptide for individual mice are shown, with the average titers (geometric means) represented
as bars. Antibody titers to J8 are shown for individual mice from the control group that had been immunized with J8 in CFA. The two experiments
were performed separately and differ in that mice received four booster injections of immunogen in exp 1 and five booster injections in exp 2. Using
analysis of variance (with Tukey’s post hoc method for multiple comparisons), antibody titers were significantly greater in mice immunized with
LCP-J8/CFA than in those immunized with J8 in CFA alone (exp 1; , P  0.001). Significant differences in antibody titers were also observed as
indicated (, P  0.001; , P  0.001; , P  0.001).
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2A). J8-specific antibodies were not detected at 3 weeks
postimmunization in the mice immunized with LCP-J8 without
adjuvant. However, after one booster injection of immunogen,
six of the nine mice had J8-specific antibodies, and after the
third booster injection, antibodies to J8 were detected in all
mice. After the final booster injection (booster injection num-
ber 4), the average J8 antibody titer in serum samples from
mice immunized with the LCP construct without adjuvant was
6.4 104 (exp 1). In the second experiment (Fig. 2B), in which
mice received a primary immunization and five booster injec-
tions each of the same immunogen, the final average J8-spe-
cific serum IgG antibody titers were 1.4  106, 5.0  104, and
7.5 105 for mice immunized with LCP-J8/CFA, LCP-J8/PBS,
and J8/CFA, respectively. IgG isotyping demonstrated strong
J8-specific IgG1, IgG2b, and IgG2a antibody responses with
lower titers or no J8-specific antibodies detected for IgG3 in
LCP-J8/CFA- and J8/CFA-immunized mice. In mice immu-
nized with LCP-J8 alone, there was a strong IgG1 response,
and IgG3 was detected in only one mouse. A few of the mice
(50%) demonstrated an IgG2a response (exp 2), and IgG2b
was barely detected in either experiment. No IgG2a was de-
tected in exp 1. Our data show that the LCP-J8 construct was
more immunogenic in CFA than was monomeric J8 peptide
given in CFA and was also immunogenic when delivered in the
absence of adjuvant. LCP-based vaccine candidates incorpo-
rating differing domains of Chlamydia trachomatis outer mem-
brane protein have also been shown in previous studies to
significantly enhance peptide immunogenicity (28). In addi-
tion, it has been shown that an LCP construct incorporating a
foot-and-mouth disease viral peptide was immunogenic, result-
ing in the induction of antipeptide antibodies in the absence of
additional adjuvant (25).
Using an in vitro indirect bactericidal assay (17, 18) which
compares the growth of bacterial population (in CFU) follow-
ing incubation with immune sera to that with control normal
mouse sera obtained from mice immunized with adjuvant
alone, we assessed the opsonic activity (measured as the per-
centage of reduction in bacterial population [in CFU]) of se-
rum IgG antibodies elicited after parenteral delivery of LCP-J8
to the homologous M1 GAS strain (Table 1 and Fig. 3). The
average levels of opsonization of M1 GAS by J8/CFA antisera
generated in exp 1 and exp 2 were 64% and 36%, respectively,
and the average level of opsonization of the pepM1 positive
control was 82% for each experiment. The average levels of
opsonization for LCP-J8/CFA antisera against M1 were 71%
(exp 1) and 68% (exp 2) and for LCP-J8 antisera against M1
were 64% (exp 1) and 76% (exp 2). Thus, results from the
opsonization of M1 GAS by LCP-J8/CFA and LCP-J8/PBS
antisera indicated that serum opsonic antibodies were induced
in mice following immunization with the LCP-J8 construct.
Moreover, the induction of opsonic antibodies was not depen-
dent on the presence of a conventional adjuvant, supporting
expectations of high efficacy of the LCP system as a self-
adjuvanting vaccine delivery modality. To confirm the specific-
ity of the opsonic antibodies induced in LCP-J8-immunized
mice, a peptide inhibition bactericidal assay was performed
which involved the preincubation of immune sera with either
100 g of J8 peptide, nonspecific peptide from Schistosoma
(EGKVSTLPLDIQIIAATMSK), or no peptide prior to the
assessment of opsonization. The levels of opsonization of M1
GAS by pooled LCP-J8/CFA and LCP-J8 antisera in the ab-
sence of peptide were 37% and 55%, respectively. Preincuba-
tion of LCP-J8/CFA antisera with J8, however, led to the
complete inhibition of opsonization. There was a 91% inhibi-
tion of opsonization for LCP-J8 antisera preincubated with J8.
The nonspecific peptide was shown to inhibit opsonization of
TABLE 1. Opsonization of GAS by LCP-J8 and control antiseraa
GAS strain
No. of bacteria
in GAS
inoculum
(CFU)
No. of bacteria
in normal
mouse serum
(mean CFU)
Immunogen
No. of bacteria in
immune serum
(mean CFU)
% Average population
reduction (CFU)
M1 (exp 1) 110 2,393 LCP-J8/CFA 694 71
LCP-J8/PBS 863 64
J8/CFA 862 64
PepM1/CFA 435 82
M1 (exp 2) 17 956 LCP-J8/CFA 310 68
LCP-J8/PBS 229 76
J8/CFA 611 36
PepM1/CFA 169 82
NS27 (exp 1) 20 6,496 LCP-J8/CFA 1,959 70
LCP-J8/PBS 2,347 64
J8/CFA 3,880 40
88/30 (exp 1) 40 5,496 LCP-J8/CFA 3,990 27
LCP-J8/PBS 3,350 39
J8/CFA 4,072 26
BSB24 (exp 1) 33 32,254 LCP-J8/CFA 17,519 46
LCP-J8/PBS 16,002 50
J8/CFA 27,342 15
PepM1/CFA 31,697 2
a By using an indirect bactericidal assay and four different GAS strains, the means of bacterial populations (in CFU) from individual serum samples plated out in
duplicate were determined following incubation of GAS of a known inoculum size in the presence of immune sera (LCP-J8/CFA, LCP-J8/PBS, J8/CFA, and
pepM1/CFA) and control normal mouse sera obtained from mice immunized with CFA in PBS alone.
b The average percentages of bacterial population reduction (in CFU) were determined by comparing the mean CFU of immune sera to those of control sera.
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LCP-J8/CFA and LCP-J8 antisera by 12% and 27%, respec-
tively. Incubation of pepM1 antisera with J8 also had little
effect on opsonization (23% inhibition of opsonization), con-
sistent with the fact that pepM1 represents the amino-terminal
half of M protein only. Together, these data indicate that
LCP-J8 induced serum opsonic antibodies specifically directed
against the M protein conserved C-region J8 peptide epitope
on GAS and that these antibodies may potentially be impor-
tant in protective immunity against GAS.
This finding prompted us to determine whether the serum
antibodies induced by LCP-J8 could opsonize other GAS
strains and might possibly be involved in mediating broadly
protective immune responses and, secondly, whether heart
FIG. 3. Opsonization of GAS by LCP-J8/CFA, LCP-J8/PBS, and
control (J8/CFA and pepM1/CFA) B10.BR mouse antisera for exp 1
(panels A and C to E) and exp 2 (B). The average percentage of
opsonization (measured as the percentage of reduction in bacterial
population [in CFU]) for each individual group is shown with the
standard error of the mean represented as a bar. Opsonization was
determined by an indirect bactericidal assay which compares the
growth of bacterial population (in CFU) following incubation in the
presence of immune sera to that of control normal mouse sera ob-
tained from mice immunized with adjuvant in PBS alone. Using anal-
ysis of variance (with Tukey’s post hoc method for multiple compari-
sons), opsonization against M1 and BSB24 GAS was significantly
greater in mice immunized with LCP-J8/CFA and LCP-J8/PBS than in
those immunized with J8 in CFA alone. , P  0.051; , P  0.008;
, P  0.031; , P  0.013.
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cross-reactive antibodies were elicited. We therefore assessed
the opsonic ability of the LCP-J8 antisera against three other
GAS strains—NS27, 8830, and BSB24 (Table 1 and Fig. 3).
Both NS27 and 8830 contain sequences identical to that of J8
in the C region, whereas BSB24 has disparities in three amino
acids in the sequence SREAKKKVEADL (the three amino
acids are indicated by boldface). LCP-J8/CFA and LCP-J8
antisera opsonized NS27 GAS with average levels of opsoniza-
tion of 70% and 64%, respectively. Less opsonization was
observed against 8830 GAS (27% for LCP-J8/CFA antisera
and 39% for LCP-J8 antisera). In the case of BSB24, LCP-J8/
CFA and LCP-J8 antisera opsonized GAS with averages of
46% and 50% opsonization, respectively. J8/CFA antisera op-
sonized NS27, 8830, and BSB24 GAS with average levels of
opsonization of 40%, 26%, and 15%, respectively. Antiserum
to pepM1 was shown not to opsonize the heterologous GAS
strain, BSB24. The induction of serum opsonic antibodies
against different GAS strains following immunization of mice
with LCP-J8 supports expectations of the efficacy of a broadly
protective GAS vaccine based on the conserved region of the
GAS M protein. Moreover, using standard sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and Western blot
analysis (18), no cross-reactivity of LCP-J8 antisera to heart
proteins in human heart and mitral valve extracts was observed.
This report has demonstrated that a GAS vaccine construct,
incorporating multiple copies of a nonhost cross-reactive con-
served region determinant of M protein, is highly immuno-
genic when administered parenterally to mice. Moreover, im-
munization with the construct led to the induction of
heterologous opsonic antibodies, even when the construct was
delivered in the absence of additional adjuvant. These findings
indicate the potential utility of the LCP system in the delivery
of a synthetic GAS vaccine with self-adjuvanting properties
with a view to the development of a mucosa-based vaccine for
human application.
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